| Hans-Günter Meyer-Thompson | Verschiedene
Intranasal Ketamine Succeeds for Resistant Depression in Phase 3 Trial
Intranasal Ketamine Succeeds for Resistant Depression in Phase 3 Trial
NEW YORK — Administering intranasal esketamine (Janssen) plus an antidepressant is safe, effective, and well tolerated in adult patients with treatment-resistant depression (TRD), a new phase 3 trial suggests. (Medscape Medical News, 11.05.2018)